Kings Path Partners LLC Reduces Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Kings Path Partners LLC cut its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 38.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,913 shares of the specialty pharmaceutical company's stock after selling 7,505 shares during the period. Kings Path Partners LLC owned about 0.05% of ANI Pharmaceuticals worth $798,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company's stock valued at $2,648,000 after purchasing an additional 13,948 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $1,128,000. Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $200,000. ProShare Advisors LLC grew its holdings in ANI Pharmaceuticals by 29.0% during the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company's stock valued at $361,000 after purchasing an additional 1,469 shares in the last quarter. Finally, Nomura Holdings Inc. grew its holdings in ANI Pharmaceuticals by 1.5% during the 4th quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company's stock valued at $11,823,000 after purchasing an additional 3,255 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock traded up $2.73 on Monday, reaching $61.45. The stock had a trading volume of 270,744 shares, compared to its average volume of 305,265. The business's 50 day moving average is $65.81 and its two-hundred day moving average is $60.76. The company has a market cap of $1.33 billion, a P/E ratio of -112.21 and a beta of 0.56. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million for the quarter, compared to analysts' expectations of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business's quarterly revenue was up 43.4% on a year-over-year basis. During the same period last year, the business earned $0.82 earnings per share. As a group, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the transaction, the insider now owns 107,317 shares of the company's stock, valued at approximately $6,487,312.65. This trade represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the firm's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the sale, the senior vice president now owns 89,897 shares in the company, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,681 shares of company stock valued at $408,498 in the last quarter. 11.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ANIP has been the subject of several research reports. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target for the company. Guggenheim reissued a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. HC Wainwright restated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.